Interferons in the treatment of multiple sclerosis: Do they prevent the progression of the disease?

Archives of Neurology

Volumn 55, Issue 12, 1998, Pages 1578-1583

  Rice, George ^a   Ebers, George ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISABILITY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; NOTE; PRIORITY JOURNAL; RELAPSE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0031675392     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.55.12.1578     Document Type: Note

References (12)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655-661.
2. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, II: MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:662-667.
3. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995; 45:1277-1285.
4. Jacobs L, Johnson KP. A brief history of the use of interferons as treatment of multiple sclerosis. Arch Neurol. 1994;51:1245-1252.
5. Kinkel RP, Rudick RA, Ransohoff RM. Rapid neurological deterioration in a patient with multiple sclerosis treated with systemic interleukin-2 and interferon-alpha 2b for metastatic renal cell carcinoma. J Neurol Neurosurg Psychiatry. 1997; 62:100.
6. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39:285-294.
7. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. Ann Neurol. 1998;43:79-87.
8. Goodkin DE, Cookfair D, Wende K, et al. Inter-and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS): Multiple Sclerosis Collaborative Research Group. Neurology. 1992;42:859-863.
9. Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon β1a on neurological disability in relapsing multiple sclerosis. Neurology. 1997;49: 358-363.
10. Noseworthy JH, Vandervoort MK, Penman M, et al. Cyclophosphamide and plasma exchange in multiple sclerosis. Lancet. 1991;337:1540-1541.
11. Noseworthy JH, O'Brien PC, and the Mayo Clinic-Canadian Cooperative MS Study Group. The Mayo Clinic-Canadian Cooperative Study of sulfasalazine in active multiple sclerosis: preliminary report. Neurology. 1997;48:A340.
12. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study, 2: predictive value of the early clinical course. Brain. 1989;112:1419-1428.